Last reviewed · How we verify

LANTHANUM CARBONATE

FDA-approved approved Small molecule Quality 5/100

LANTHANUM CARBONATE is a drug. It is currently FDA-approved (first approved 2004).

At a glance

Generic nameLANTHANUM CARBONATE
ModalitySmall molecule
PhaseFDA-approved
First approval2004

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about LANTHANUM CARBONATE

What is LANTHANUM CARBONATE?

LANTHANUM CARBONATE is a Small molecule drug.

When was LANTHANUM CARBONATE approved?

LANTHANUM CARBONATE was first approved on 2004.

What development phase is LANTHANUM CARBONATE in?

LANTHANUM CARBONATE is FDA-approved (marketed).

What are the side effects of LANTHANUM CARBONATE?

Common side effects of LANTHANUM CARBONATE include Nausea, Vomiting, Abdominal pain, Diarrhea, Hypocalcemia. Serious adverse events: Intestinal perforation, Intestinal obstruction, Ileus, Subileus.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing